ADO 3.67% 2.1¢ anteotech ltd

Bard1 Life Sciences, page-13

  1. 1,101 Posts.
    lightbulb Created with Sketch. 912
    Maybe nothing, but then again maybe something, especially since Bard's chairman is Anteos Geoff Cummings.
    Could Anteobind be being used here ...
    FYI ... Bard are developing a range of cancer tests. Initial results are indicating 100% specificity and over 95% sensitivity ...

    BARD1’s EXO-NET™ product allows for fast, accurate and efficient capture and isolation of exosomes from any liquid biopsy sample

    The EXO-NET™ matrix that is coated onto magnetic beads has the following features: ....
    ....
    Rapid: Time from sample to exosome isolation is within 15 minutes ....
    ... in a fraction of the time (15 minutes versus 6-12 hours).


    Exosomes are actively secreted by most cells, including primary or metastatic tumour cells, into biological fluids including serum, plasma, urine, breast milk, and saliva. Studies have found that the analysis of exosome-associated nucleic acids, proteins and/or lipids can indicate the presence of a range of cancers, including pancreatic cancer, colorectal cancer, breast cancer, and non-small cell lung cancer.
 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
-0.001(3.67%)
Mkt cap ! $52.28M
Open High Low Value Volume
2.2¢ 2.3¢ 2.1¢ $7.812K 349.8K

Buyers (Bids)

No. Vol. Price($)
7 828094 2.1¢
 

Sellers (Offers)

Price($) Vol. No.
2.2¢ 1102151 4
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
ADO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.